Wereport a case of amyotrophic lateral sclerosis (ALS) with anti-acetylcholine receptor (AChR) antibody in a 73-year-old female patient. She showed the typical course ofALS. She had no clinical findings ofmyasthenia gravis and had never undergone neurotoxin therapy using snake venom. Anti-AChRantibody was positive with a titer of 0.50 nmol// on admission. Wetraced the titers during the progression of ALS;the titer was positive when muscle weakness worsened, and it became negative whenthe general condition becamestable. Wesuppose that the occurrence of anti-AChR antibody may be partially relevant with abnormalities at the neuromuscular junction during the progression of ALS. (Internal Medicine 36: 312-315, 1997) 
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive disorder of upper and lower motor neurons in the cerebral cortex, brain stem, and spinal cord, with clinical manifestation of muscular weakness, atrophy, and hyper-reflexia (1) . The onset of this disease is gradual and its clinical course is relentlessly progressive and widespread. However, intelligence and awareness are typically preserved to the end. Although the etiopathogenesis ofALS is still unclear, the possibility ofimmunological disturbance has been suggested (2) . Here, we report a case ofALS with anti-acetylcholine receptor (AChR) antibody which is considered as a specific diagnostic markerformyasthenia gravis (3) . We also discuss the significance of the antiAChR antibody in ALS.
Case Report
A 73-year-old woman was referred to the hospital, complaining ofdysphagia in August 1991. She was born of healthy nonconsanguineous parents with no family history of neuromuscular disease. At the time of her birth, the delivery and early development were normal. Physical and psychomotor development had been normal. From November1990, her voice became husky and the volume had gradually decreased. In March 1991 , she developed aphonia and soon dysphagia. In particular, swallowing liquid was more difficult for her than swallowing something solid. She felt no worsening of symptoms when she was tired. On admission, body height was 140 cmandbody weightwas 37 kg. Herconsciousness was alert and the state of nutrition was moderate. Blood pressure was 120/70 mmHgand pulse rate was 76/min and regular. Vision and hearing were not impaired. Neurological examination revealed bulbar palsy. Fasciculation was observed in her tongue and left lower leg. Generalized hyperreflexia and bilateral pathological reflexes were present. Nodisturbance of the sensory system or autonomic nervous system were observed. Additionally, there was no blepharoptosis at any time. The initial blood count showed a hematocrit of 32.9%, leukocyte count of 4500 with 2% of stab and 62% of segment form, 29%lymphocytes, 6% monocytes. Theerythrocyte sedimentation rate was 58 mm/h. Other laboratory data on admission showed normal liver function, serum creatinine 0.8 mg/dl, total protein 7. 1 g/dl, albumin 3.9 g/dl. The fraction of serum protein showed albumin 53%, a!-globulin 6.2%, a2-globulin 15.5%, p-globulin 9.5%, andyglobulin 16.1%. There was no finding of monoclonal gammopathy in the protein-electrophoresis. Serum creatine kinase was 79 IU// (control range less than 197 IU//) and there were no abnormalities of electrolytes. Interestingly, serumantiAChRantibody level was 0.50 nmol// (control range less than 0.2 nmol//) and it was positive. The assay of anti-AChR antibody is divided into two types. One measures the activity of uninhibitory anti-AChR antibody using anti-human IgG, the other measures the activity of inhibitory anti-AChR antibody. In this case, we measured the activity of uninhibitory antiAChRantibody. Anti-AChR antibody concentration was measured by immunoprecipitation using [ 1 25I] a-bungarotoxin-labeled AChRas the antigen and was expressed as moles of [125I] ocbungarotoxin binding sites precipitated per liter of serum (4) . Theinitial chest X-ray was normal and thymoma were not found by the chest computed tomography. Tensilon test was negative. The electromyography (EMG) revealed a fasciculation potential in the left-gastrocnemius at rest (Fig. 1) , while we could not recognize a fibrillation potential in the EMG.The voltage ofneuromuscular units was at the level of 1.5 mV^kO mVat voluntary contraction. The interference was poor at maximal contraction. By repetitive stimulation in the leftgastrocnemius, there were no findings ofwanning or waxing by the stimulation of left-gastrocnemius with 3 c/s. These findings indicated neurogenic changes. A sagittal scanning of the magnetic resonance image (MRI) showed remarkable tongue atrophy in the anterior half and fatty change of the tongue muscle (Fig. 2) . Brain MRIshowed no abnormality, except a slight dilatation of the lateral ventricle. Therefore, we madea diagnosis ofALS, not myasthenia gravis. Wethen started conservative therapy with nasal nutrition. Figure 3 shows the patient's clinical course and the change in serum levels of anti-AChR antibody. We traced the titers of the antibody during the progression of ALS. From November 1990, dysarthria had worsened. In March 1991, dysphagia was added, and from August 1991 , the weakness of upper and lower extremities had developed. At that time, anti-AChR antibody was positive with a titer of 0.50 nmol//. After hospitalization, the general condition became stable by nasal nutrition, except for aspiration pneumonia. In October 1991, the titer decreased to a level of 0.02 nmol//. From April 1992, dyspnea by weakness of respiratory muscles appeared. As the weaknessof the respiratory muscles worsened, the titer ofanti-AChR antibody increased to a level of 0.25 nmol//. During the progression of ALS, serum creatinine slightly decreased to a level of 0.4 mg/dl and serum GOTincreased to a level of 137 IU// in April 1992. Although we performed mechanical ventilation, the general condition of the patient gradually worsened and she died of respiratory failure in April 1993. In addition, we could not point out any findings ofthymoma, thymic hypertrophy, or other autoimmune disease, such as thyroiditis at autopsy.
Discussion
ALS is a neurodegenerative disorder characterized by a progressive loss of motor neurons in the central nervous system. Despite extensive investigation, the etio-pathogenesis remains unkown( 1). Previous reports showed that a numberof factors are associated with the pathogenesis, such as virus infection (5, 6), heavy metal intoxication (7), immunological disturbances (8, 9) , metabolic disorders (10), oxidative stress (ll), and genetic mutation of the superoxide dismutase gene (12). However, the precise pathogenesis for sporadic cases of ALSre- In the present case, the patient had never undergone neurotoxin therapy for ALSand had no clinical manifestations for myasthenia gravis. Wetraced the titers of anti-AChR antibody during the progression of muscle weakness. Whenmuscle weakness of extremities had appeared in August 1991, the titer ofanti-AChR antibody was 0.50 nmol// (control range less than 0.20 nmol//). In October 1991, about two months after the hospitalization, the titer decreased to the level of 0.20 nmol//, when the clinical findings were becoming stable. In April 1992, whenrespiratory muscle weakness developed, the titer slightly increased to 0.25 nmol//. Wecould notpointout any findings of thymoma,thymic hypertrophy, or other autoimmune disease, such as thyroiditis at autopsy. Therefore, we concluded that this was a rare ALScase with anti-AChR antibody. As far as we know, this is the first report in which the titers of anti-AChR antibody were traced during the progression of ALS. Wesuppose that the occurrence of anti-AChR antibody may be partially relevant to the abnormalities at the neuromuscular junction in ALS. Previous reports showed that immunoglobulin (Ig) G from human ALS patients could enhance the release of acetylcholine from axon terminals (15). HumanALS IgG also selectively interacts with calcium channels and alters calcium channel function ( 1 6) . These phenomena at the neuromuscular junction lead to motor neuron overactivity and may gradually cause muscle weakness. However, the mechanismby which the anti-AChR antibody is produced in ALS is not known. One possibility is that the occurrence of the antibody might be an autoimmune reaction against degenerative AChRat the neuromuscular junction. Further investigation is necessary to define the specific relation with the anti-AChR antibody and the progression of ALS.
